Literature DB >> 30250586

A study of the application of TAP combined with transvaginal ultrasound in the diagnosis of early-stage endometrial cancer.

Anjun Ma1, Dianxia Fan2, Fangli Yan1.   

Abstract

The aim of the study was to investigate the application of tumor abnormal protein (TAP) combined with transvaginal ultrasound in the diagnosis of early-stage endometrial cancer. A total of 248 patients with suspected endometrial cancer who were admitted to the Gynecology Department of the Second People's Hospital of Liaocheng from September 2013 to September 2015 were selected and randomly divided into the control (n=124) and the observation group (n=124). The control group received conventional ultrasound examination, while the observation, underwent TAP combined with conventional ultrasound examination. Differences in the definite diagnostic results of the two diagnostic methods and curettage were compared, and the application of TAP combined with transvaginal ultrasound in the diagnosis of early-stage endometrial cancer was studied. Among 248 patients receiving hysteroscopy and diagnostic curettage examination, there were 75 patients with early-stage endometrial cancer, and 173 benign patients. The total diagnostic accordance rate of conventional ultrasound for endometrial lesions was 87.90% (n=218), and the accordance rate for early-stage endometrial carcinoma was 90.67% (n=68); the total diagnostic accordance rate of TAP combined with vaginal ultrasound for endometrial lesions was 94.35% (n=234), and for early-stage endometrial cancer was 94.67% (n=71); of TAP combined with conventional ultrasound for endometrial lesions and endometrial cancer were higher than those of simple conventional ultrasound (P<0.05). The area under the curve (AUC) of conventional ultrasound in the diagnosis of endometrial cancer was 0.754 [95% confidence interval (CI): 0.211-2.534]. The AUC of TAP combined with vaginal ultrasound in the diagnosis of endometrial cancer was 0.814 (95% CI: 0.517-0.932), and a comparison between the two groups was statistically significant (P=0.011). The accuracy rate of TAP combined with transvaginal ultrasound in the diagnosis of early-stage endometrial cancer is relatively high, and it is worthy promoting and applying in clinical practice.

Entities:  

Keywords:  application value; endometrial cancer; hysteroscopy; tumor abnormal protein; vaginal ultrasound

Year:  2018        PMID: 30250586      PMCID: PMC6144540          DOI: 10.3892/ol.2018.9250

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

Endometrial cancer is a malignant tumor in the female reproductive system with a high incidence rate, accounting for approximately 25% of all the female reproductive system tumors, and its incidence in developed countries (ranking fourth) is higher than that in developing countries (ranking seventh) (1–2). Endometrial cancer often occurs in perimenopausal and postmenopausal women (3), and a present investigation report has shown that the age of patients at the onset of endometrial cancer becomes smaller and smaller (4). Although the five-year survival rate of patients has improved with the development of medical technology, the prognosis of some endometrial cancer patients is poor, causing death (5,6); thus, the early diagnosis of endometrial cancer patients is crucial. The mortality rate of patients with endometrial cancer in the advanced stage is much higher than that of patients in the early stage (7). Improving the specificity and sensitivity of the diagnosis of endometrial cancer patients is an important means to improve the survival rate of patients. Ultrasound plays an extremely important role in the diagnosis of tumors. Ultrasound has many advantages such as noninvasiveness, high diagnostic sensitivity, no radioactivity and simple methods. It has been widely used in the diagnosis of tumors (8,9). In addition, ultrasound can reduce the invasive examination for patients and risks of invasive operation for patients through its initial screening (10). Tumor abnormal protein (TAP) is a kind of abnormal glycoprotein and calmodulin complex expressed after the mutation of oncogenes and tumor suppressor genes in cells (11). It has been reported that abnormal glycoproteins are closely related to the occurrence, development, invasion, metastasis and prognosis of cancers (12). Therefore, the detection of TAP in serum can provide an important reference for the clinical diagnosis of tumors. In the present study, 248 patients with suspected endometrial cancer who were admitted to the Gynecology Department of The Second People's Hospital of Liaocheng (Linqing, China) from September 2013 to September 2015 were selected, and the diagnostic accordance rate of TAP combined with vaginal ultrasound was analyzed.

Materials and methods

Clinical data

A total of 248 women patients (average age of 41.6±11.6 years) with suspected endometrial cancer who were admitted to the Gynecology Department of The Second People's Hospital of Liaocheng from September 2013 to September 2015 were selected and randomly divided into the control (n=124) and the observation group (n=124). The control group received conventional ultrasound examination; the observation, underwent TAP combined with conventional ultrasound examination, and all patients were definitely diagnosed by hysteroscopy and diagnostic curettage examination. Patients without tumor history, without liver, kidney and other organ dysfunction, and without abnormal hemorrhage or coagulation dysfunction before operation were included. Patients with unqualified curettage specimens, receiving treatment before, with excessive large tumor mass or with other pulmonary or chest wall diseases were excluded. This study was approved by the Ethics Committee of the Second People's Hospital of Liaocheng, and patients or their family members signed informed consent.

Instruments and methods

Hitachi Hivision Avivs color Doppler ultrasound diagnostic machine (Hitachi, Ltd., Tokyo, Japan) was applied for conventional ultrasound examination so as to observe patients' tumor diameter, shape, edge status, internal echo information and whether there were space occupying lesions. At the same time, the fasting whole blood was collected from the included patients in the early morning, and TAP detection was conducted. Abnormal carbohydrate chain glycoprotein detection kits were purchased from Thermo Fisher Scientific, Inc., (Waltham, MA, USA), and the image analyzer for TAP detection was purchased from Zhejiang Aicor Medical Technology Co., Ltd. (Zhejiang, China).

Statistical analysis

The experimental results were analyzed by using SPSS 22.0 software (IBM Corp., Armonk, NY, USA), and the analysis of variance followed by post hoc test (Least Significant Difference) was used for compari-sons among multiple groups. Count data were expressed as percentage and detected by χ2 test. The sensitivity and specificity of conventional ultrasound and TAP combined with conventional ultrasound in the diagnosis of endometrial cancer were calculated, respectively. T0he diagnostic values of conventional ultrasound and the combination of the two methods in the diagnosis of endometrial cancer were studied by using the receiver operating characteristic (ROC) curve. P<0.05 was considered to indicate a statistically sgnificant difference.

Results

Basic data

In this study, 248 patients at an average age of 41.6±11.6 years with suspected endometrial cancer were included. After the pathological diagnosis by curettage, it was found that there were 60 cases of endometrial polyps, 96 of endometrial hyperplasia, 17 of uterine fibroids and 75 cases of endometrial cancer. In addition, the menopause data of patients were collected, in which there were 43 premenopausal patients (17.34%), confirming that the age of patients at the onset of endometrial cancer becomes smaller (Table I).
Table I.

Clinical data of patients.

Clinical dataControl group (n=124)
Age (years)41.6±11.6
Definite diagnostic results
  Endometrial polyps60
  Endometrial hyperplasia96
  Uterine fibroids17
  Endometrial cancer75
Nationality n (%)
  Han219 (88.31)
  National minority29 (11.69)
Place of residence n (%)
  City165 (66.53)
  Countryside83 (33.47)
Menopausal status n (%)
  Premenopause43 (17.34)
  Postmenopause205 (82.66)

Diagnostic results of the two programs

Of 248 patients receiving hysteroscopy and diagnostic curettage examination, there were 75 patients with early-stage endometrial cancer and 173 benign patients (including 60 patients with endometrial polyps, 96 with endometrial hyperplasia and 17 with uterine fibroids). The total diagnostic accordance rate of conventional ultrasound for endometrial lesions was 87.90% (n=218), and for early-stage endometrial carcinoma was 90.67% (n=68). For patients with endometrial polyps, the rate was 88.33% (n=53); with endometrial hyperplasia was 87.50% (n=84); with uterine fibroids was 76.47% (n=13). For TAP combined with vaginal ultrasound for endometrial lesions, the rate was 94.35% (n=234), and for early-stage endometrial cancer was 94.67% (n=71). For diagnosis for patients with endometrial polyps the rate was 95.00% (n=57), with endometrial hyperplasia it was 93.75% (n=90), and with uterine fibroids it was 94.12% (n=16); The diagnostic accordance rates of TAP combined with conventional ultrasound for endometrial lesions were higher than those of simple conventional ultrasound (P<0.05) (Table II). Imaging manifestations of conventional ultrasound (Table III).
Table II.

Diagnostic accordance rates of TAP combined with conventional ultrasound and conventional ultrasound.

RateConventional ultrasoundTAP combined with conventional ultrasoundP-value
Total diagnostic accordance rate218 (87.90)234 (94.35)0.031
Accordance rate of endometrial cancer68 (90.67)71 (94.67)0.047
Accordance rate of endometrial hyperplasia84 (87.50)90 (93.75)0.032
Accordance rate of endometrial polyps53 (88.33)57 (95.00)0.024
Accordance rate of uterine fibroids13 (76.47)16 (94.12)0.017
Table III.

Imaging manifestations of conventional ultrasound.

Endometrial polypsEndometrial hyperplasiaUterine fibroidsEndometrial cancer
Uterine volumeNo obvious increaseNo obvious change; increase in some partsIncreasedObviously increased
EchoHypoecho Equal echo HyperechoSlightly enhancedHypoecho; hyperecho in tiny minorityUnevenly thickened
Intimal thickness changeNo significantThickenedThickenedThickened
Lesion borderClearClear uterine cavity lineRelatively clearRough surface; some unclear or even vanished borders
Lesion area liquidation/calcificationCalcification in few lesion areasNo liquidation/calcificationLiquidation/calcification on in few lesion areasLiquidation in some lesion areas

TAP detection results

The image analyzer for TAP detection was used to analyze the polarity of TAP detection results, which showed that the positive rate of TAP detection was 86.67% (n=65) in patients with endometrial cancer and 4.37% (n=8) with benign lesions; there was a significant difference between the two groups of patients (P<0.05). Among the patients with benign lesions and positive TAP detection results, there were 5 cases of uterine fibroids, 2 of endometrial polyps and 1 of endometrial hyperplasia (Fig. 1).
Figure 1.

TAP detection results. The image analyzer for TAP detection is used to analyze the polarity of TAP detection results, which show that the positive rate of TAP detection in patients with endometrial cancer is 86.67% (n=65) and in patients with benign lesions was 4.37% (n=8). There is a significant difference between the two groups of patients (P<0.05). Of the patients with benign lesions with positive TAP detection results, there are 5 cases of uterine fibroids, 2 of endometrial polyps and 1 of endometrial hyperplasia. TAP, tumor abnormal protein.

Sensitivity and specificity of the two programs

The sensitivity and specificity of conventional ultrasound to endometrial cancer were 85.7 and 89.7%, respectively, and those of TAP combined with vaginal ultrasound to endometrial cancer were 90.0 and 92.8%, respectively. ROC analysis results revealed that the AUC of convention ultrasound in the diagnosis of endometrial cancer was 0.754 [95% confidence interval (CI): 0.211–2.534], and that of TAP combined with vaginal ultrasound in the diagnosis of endometrial cancer was 0. 814 (95% CI: 0.517–0.932); the difference between the two programs was significant (P=0.011) (Fig. 2).
Figure 2.

ROC curves of the two programs in the diagnosis of endometrial cancer. The AUC of convention ultrasound in the diagnosis of endometrial cancer is 0.754 [95% CI: 0.211–2.534], and that of TAP combined with vaginal ultrasound in the diagnosis of endometrial cancer is 0. 814 (95% CI: 0.517–0.932); the difference between the two programs is significant (P=0.011). ROC, receiver operating characteristic; AUC, area under the curve; TAP, tumor abnormal protein; CI, confidence interval.

Discussion

Prognoses of endometrial cancer in the advanced stage and some special cases of endometrial cancer are very poor, and their 5-year survival rates are relatively low, so the early diagnosis of patients with endometrial cancer is very necessary (6,7). TAP is a type of complex that is expressed and released by tumor cells and can be found in the blood of tumor patients, which provides a very convenient specimen for the early screening of tumors (13,14). TAP has become a hot research object for researchers, especially on the screening and early diagnosis of tumors, since it was discovered by the Union of Soviet Socialist Republics (USSR) scholars, Kostyantin, A. and Galakhin (15,16). However, there are few diagnostic studies in patients with endometrial cancer in the early stage. This study was expected to provide a basis for clinical diagnosis of endometrial cancer in the early stage and improve the survival rate of patients. In the present study, 248 patients with suspected endometrial cancer were included, and with other tumors were excluded. TAP combined with conventional ultrasound was used for diagnosis, whose results were compared with those of diagnostic curettage detection, so as to analyze the value of TAP combined with conventional ultrasound in the diagnosis of endometrial cancer in the early stage. The study's results showed that the diagnostic accordance rate of TAP for patients with endometrial cancer was 86.67%, and that of conventional ultrasound for patients with endometrial cancer was 90.67%, and that of the combination of the two was 94.35%; the diagnostic accordance rate of TAP and conventional ultrasound for patients with endometrial cancer were lower than that of the combination of the two (P<0.05), indicating that TAP detection can improve the diagnostic effect of conventional ultrasound on endometrial cancer. In addition, ROC curve results also revealed that the combined diagnostic method had a high diagnostic value (AUC=0.814). The sensitivity of the TAP detection system is the expressed TAP when the number of tumor cells reaches 100,000 and above, but it takes about one year for the number of tumor cells to proliferate to 100,000 before the tumor has not formed a mass, which is extremely important for the treatment and survival of patients, especially of those with malignant tumors with fast development and poor prognosis (17–20). There are few researchers studying the effect of TAP detection in the diagnosis of endometrial cancer in the early stage, so the conclusions in this study still need to be further validated. This study also had its advantages: All patients with past tumor history were excluded to avoid the interference in TAP detection; a self-controlled test was conducted so that the interference of test samples was avoided. TAP is also used in many kinds of cancers, such as gastric, thyroid and colorectal cancer, and it is of positive significance in improving the accordance rate of tumor diagnosis (21–22). These indirectly confirmed the diagnostic value of TAP in the diagnosis of endometrial cancer. Benign endometrial lesions were also analyzed, which showed that approximately 20–40% of patients suffered from atypical endometrial hyperplasia before the onset of endometrial cancer. TAP combined with vaginal ultrasound also has a relatively diagnostic high accordance rate (93.75%) for endometrial hyperplasia, and among patients with TAP positive detection results, there was 1 case of endometrial hyperplasia. Due to the limitation of experimental time, the patients were not followed-up, and further investigation is needed for confirmation of the results. In summary, TAP combined with transvaginal ultrasound in the diagnosis of early-stage endometrial cancer has a higher accuracy rate, and it is worth promoting and applying in clinical practice.
  21 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

2.  Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.

Authors:  Michel Claudon; Christoph F Dietrich; Byung Ihn Choi; David O Cosgrove; Masatoshi Kudo; Christian P Nolsøe; Fabio Piscaglia; Stephanie R Wilson; Richard G Barr; Maria C Chammas; Nitin G Chaubal; Min-Hua Chen; Dirk Andre Clevert; Jean Michel Correas; Hong Ding; Flemming Forsberg; J Brian Fowlkes; Robert N Gibson; Barry B Goldberg; Nathalie Lassau; Edward L S Leen; Robert F Mattrey; Fuminori Moriyasu; Luigi Solbiati; Hans-Peter Weskott; Hui-Xiong Xu
Journal:  Ultrasound Med Biol       Date:  2012-11-05       Impact factor: 2.998

3.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Authors:  M Minhaj Siddiqui; Soroush Rais-Bahrami; Baris Turkbey; Arvin K George; Jason Rothwax; Nabeel Shakir; Chinonyerem Okoro; Dima Raskolnikov; Howard L Parnes; W Marston Linehan; Maria J Merino; Richard M Simon; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

4.  Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients.

Authors:  Xue-Yan Wu; Xin-En Huang
Journal:  Asian Pac J Cancer Prev       Date:  2015

Review 5.  Endometrial cancer: a review and current management strategies: part I.

Authors:  William M Burke; James Orr; Mario Leitao; Emery Salom; Paola Gehrig; Alexander B Olawaiye; Molly Brewer; Dave Boruta; Jeannine Villella; Jeanine Villella; Tom Herzog; Fadi Abu Shahin
Journal:  Gynecol Oncol       Date:  2014-06-04       Impact factor: 5.482

6.  Self-efficacy, quality of life, and weight loss in overweight/obese endometrial cancer survivors (SUCCEED): a randomized controlled trial.

Authors:  M L McCarroll; S Armbruster; H E Frasure; M D Gothard; K M Gil; M B Kavanagh; S Waggoner; V E von Gruenigen
Journal:  Gynecol Oncol       Date:  2013-12-22       Impact factor: 5.482

7.  Tumor abnormal protein (TAP) examination contributes to primary diagnosis of bladder cancer.

Authors:  Liqing Zhang; Xiuxia Guo; Yongzheng Min; Jianjiang Xu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.

Authors:  N Colombo; C Creutzberg; F Amant; T Bosse; A González-Martín; J Ledermann; C Marth; R Nout; D Querleu; M R Mirza; C Sessa
Journal:  Ann Oncol       Date:  2015-12-02       Impact factor: 32.976

9.  Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.

Authors:  R T Chlebowski; G L Anderson; G E Sarto; R Haque; C D Runowicz; A K Aragaki; C A Thomson; B V Howard; J Wactawski-Wende; C Chen; T E Rohan; M S Simon; S D Reed; J E Manson
Journal:  J Natl Cancer Inst       Date:  2015-12-14       Impact factor: 13.506

10.  Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk.

Authors:  Luis G Carvajal-Carmona; Tracy A O'Mara; Jodie N Painter; Felicity A Lose; Joe Dennis; Kyriaki Michailidou; Jonathan P Tyrer; Shahana Ahmed; Kaltin Ferguson; Catherine S Healey; Karen Pooley; Jonathan Beesley; Timothy Cheng; Angela Jones; Kimberley Howarth; Lynn Martin; Maggie Gorman; Shirley Hodgson; Nicholas Wentzensen; Peter A Fasching; Alexander Hein; Matthias W Beckmann; Stefan P Renner; Thilo Dörk; Peter Hillemanns; Matthias Dürst; Ingo Runnebaum; Diether Lambrechts; Lieve Coenegrachts; Stefanie Schrauwen; Frederic Amant; Boris Winterhoff; Sean C Dowdy; Ellen L Goode; Attila Teoman; Helga B Salvesen; Jone Trovik; Tormund S Njolstad; Henrica M J Werner; Rodney J Scott; Katie Ashton; Tony Proietto; Geoffrey Otton; Ofra Wersäll; Miriam Mints; Emma Tham; Per Hall; Kamila Czene; Jianjun Liu; Jingmei Li; John L Hopper; Melissa C Southey; Arif B Ekici; Matthias Ruebner; Nichola Johnson; Julian Peto; Barbara Burwinkel; Frederik Marme; Hermann Brenner; Aida K Dieffenbach; Alfons Meindl; Hiltrud Brauch; Annika Lindblom; Jeroen Depreeuw; Matthieu Moisse; Jenny Chang-Claude; Anja Rudolph; Fergus J Couch; Janet E Olson; Graham G Giles; Fiona Bruinsma; Julie M Cunningham; Brooke L Fridley; Anne-Lise Børresen-Dale; Vessela N Kristensen; Angela Cox; Anthony J Swerdlow; Nicholas Orr; Manjeet K Bolla; Qin Wang; Rachel Palmieri Weber; Zhihua Chen; Mitul Shah; Paul D P Pharoah; Alison M Dunning; Ian Tomlinson; Douglas F Easton; Amanda B Spurdle; Deborah J Thompson
Journal:  Hum Genet       Date:  2014-12-09       Impact factor: 4.132

View more
  7 in total

1.  High Expression of Tumor Abnormal Protein Preoperatively Predicts Poor Prognosis of Patients With Esophageal Squamous Cell Carcinoma.

Authors:  Yuanjun Cheng; Qianru Fang; Yongbing Chen; Guohui Zang; Jie Yao
Journal:  Front Surg       Date:  2021-02-24

2.  Effect of Combination of Traditional Chinese Medicine with Western Medicine on Endometrial Carcinoma and Its Influence on Ultrasound, MRI, Tumor Markers HE4 and CA125.

Authors:  Xia Gao; Qiuying Li; Yanwen Qu; Jinzhi Zhang; Yougang Xing; Shichun Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-02       Impact factor: 2.629

3.  Clinical Value Analysis of Combined Vaginal Ultrasound, Magnetic Resonance Dispersion Weighted Imaging, and Multilayer Spiral CT in the Diagnosis of Endometrial Cancer Using Deep VGG-16 AdaBoost Hybrid Classifier.

Authors:  Xiaoyi Wang; Rong Zhang
Journal:  J Oncol       Date:  2022-04-26       Impact factor: 4.375

4.  Increased Expression of TAP Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer.

Authors:  Yuanjun Cheng; Yongbing Chen; Guohui Zang; Bin Chen; Jie Yao; Wenguang Zhang; Haibing Wang; Liu Yu; Pinghai He; Youming Zhang; Hanqing Wu
Journal:  Cancer Manag Res       Date:  2020-03-13       Impact factor: 3.989

5.  Insights into the role of tumor abnormal protein in early diagnosis of cancer: A prospective cohort study.

Authors:  Lu-Xi Li; Bin Zhang; Rui-Zhi Gong
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

6.  Clinical value of prostate-specific antigen combined with tumor abnormal protein (TAP) in the diagnosis of prostate puncture.

Authors:  Yu Guan; Shuiping Yin; Chaozhao Liang
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

7.  Identification of immune-related genes that predict prognosis and risk of bladder cancer: bioinformatics analysis of TCGA database.

Authors:  Liqiang Guo; Qiong Wu; Zhen Ma; Mingzhen Yuan; Shengtian Zhao
Journal:  Aging (Albany NY)       Date:  2021-07-30       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.